Medtech’s Role In The Future Of GLP-1 Therapy
Executive Summary
As well as making waves in the treatment of obesity, debate has been stirring around the ability of GLP-1s to combat drug addiction, manage heart disease and also protect individuals against Parkinson’s disease. How can medtechs get in on the potential gains?
You may also be interested in...
Can New Generation GLP-1s Overcome The Adherence Hurdle?
Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term.
Huma Granted Class II Clearance By FDA For Its Disease-Agnostic Platform
Huma’s platform is now the only remote patient monitoring platform approved in both the US and Europe that is able to aid clinicians in their work.
Minute Insight: SpectralMD Signs Another Contract With BARDA, Worth $149m
The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.